Malta - English - Medicines Authority

cis bio international route nationale 306-saclay, bp 32, 91192, gif-sur-yvette cedex, france - fluorocholine - solution for injection - fluorocholine (18-f) 225 mbq/ml - diagnostic radiopharmaceuticals

Malta - English - Medicines Authority

iason gmbh feldkirchner str. 4, a-8054 graz, austria - fluorocholine - solution for injection - fluorocholine (18-f) 100 mbq/ml - diagnostic radiopharmaceuticals

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cis bio international - fluorocholine (18 f) 225 mbq/ml - solution for injection - 225 mbq/ml - fluorocholine (f-18) 225 mbq/ml - fluoromethylcholine (18f)

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

advanced accelerator applications - fluorocholine (18 f) 222 mbq/ml - solution for injection - 222 mbq/ml - fluorocholine (f-18) 222 mbq/ml - fluoromethylcholine (18f)

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

iason labormedizin gmbh & co. kg - fluorocholine (18 f) 1 gbq/ml - solution for injection - 1 gbq/ml - fluorocholine (f-18) - fluoromethylcholine (18f)

European Union - English - EMA (European Medicines Agency)

curium pet france - piflufolastat (18f) - prostatic neoplasms - diagnostic radiopharmaceuticals - this medicinal product is for diagnostic use only.pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent.pylclari is indicated for use with positron emission tomography (pet).

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

iason labormedizin gmbh & co. kg - fluorocholine (18 f) 1 gbq/ml - solution for injection - fluoromethylcholine (18f)

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - cytarabine 100 mg/ml - solution for injection - 100 mg/ml - active: cytarabine 100 mg/ml excipient: water for injection - cytarabine is indicated primarily for: · induction and maintenance of remission in acute myelocytic leukaemia of both adults and children. it has also been found to be useful in the treatment of other leukaemias such as · acute lymphocytic leukaemia · chronic myelocytic leukaemia (blast phase). cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy. children with non-hodgkin's lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine. remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity. cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.